

83  
acid sequence, which has at least 80% identity with the polypeptide of SEQ ID NO:2  
when said expression system is present in a host cell.

84  
11. (AMENDED) A process for producing an IGS1 polypeptide comprising  
culturing a host cell of claim 7 under conditions sufficient for the production of said  
polypeptide and recovering the polypeptide from the culture.

12. (AMENDED) A process for producing a cell which produces an IGS1  
polypeptide comprising transforming or transfecting a cell with the expression system of  
claim 6, wherein the cell produces an IGS1 polypeptide.

13. (AMENDED) An IGS1 polypeptide comprising an amino acid sequence,  
which is at least 80% identical to the amino acid sequence of SEQ ID NO:2.

85  
16. (AMENDED) A method for the treatment of a subject in need of enhanced  
activity or expression of the IGS1 polypeptide of claim 13 comprising at least one of:  
(a) administering to the subject a therapeutically effective amount of an agonist to  
said polypeptide; and  
(b) providing to the subject an isolated polynucleotide comprising a nucleotide  
sequence that has at least 80% identity to a nucleotide sequence encoding the  
IGS1 polypeptide of SEQ ID NO:2 or a nucleotide sequence complementary to  
said nucleotide sequence, wherein the polynucleotide directs production of said  
polypeptide activity in vivo.

17. (AMENDED) A method for the treatment of a subject having need to inhibit  
activity or expression of a IGS1 polypeptide as claimed in claim 13 comprising at least  
one of:

FINNEGAN  
HENDERSON  
FARABOW  
GARRETT &  
DUNNER LLP

1300 I Street, NW  
Washington, DC 20005  
202.408.4000  
Fax 202.408.4400  
www.finnegan.com

- Cont  
B5
- (a) administering to the subject a therapeutically effective amount of an antagonist to said polypeptide;
  - (b) providing to the subject an isolated polynucleotide that inhibits the expression of the nucleotide sequence encoding said polypeptide; and
  - (c) administering to the subject a therapeutically effective amount of a polypeptide that competes with said polypeptide for its ligand.

18. (AMENDED) A process for diagnosing a disease or a susceptibility to a disease in a subject, wherein the disease is related to expression or activity of the IGS1 polypeptide of claim 13 in a subject comprising at least one of:

- (a) determining the presence or absence of a mutation in the nucleotide sequence encoding said IGS1 polypeptide in the genome of said subject; and
- (b) analyzing for the presence or amount of the IGS1 polypeptide expression in a sample derived from said subject.

Please add the following new claim:

- B6
25. (NEW) The isolated polynucleotide of claim 1, wherein the nucleotide sequence has at least 90% identity to the nucleotide sequence of (a) and (b).

#### REMARKS

Applicants respectfully request that the amendments to the specification and the claims be entered before the application is examined.

The amendment to the specification corrects a citation. This amendment does not add new matter.

FINNEGAN  
HENDERSON  
FARABOW  
GARRETT &  
DUNNER LLP

1300 I Street, NW  
Washington, DC 20005  
202.408.4000  
Fax 202.408.4400  
www.finnegan.com